弱毒生ポリオワクチンの世界市場レポート (2025年)

弱毒生ポリオワクチンの市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.9％で27億1,000万米ドルに成長します。予測期間中の成長は、ワクチンの安定性と保存性の向上、紛争地域でのポリオ患者の復活、撲滅活動におけるドナー疲労、定期予防接種プログラムの拡大、より安全な弱毒生ワクチン株の研究開発の増加などに起因すると考えられます。この期間に予想される主な動向としては、ワクチン由来ポリオウィルスの出現、新しい経口ポリオワクチンの開発、ワクチン製剤の技術的発展、デジタル技術の統合、官民連携の強化などが挙げられます。

予防接種プログラムの拡大は、今後数年間の弱毒生ポリオワクチン（LAPV）市場の成長に大きく貢献すると予想されます。予防接種プログラムとは、感染症の蔓延を防ぐために、政府や保健機関、その他の機関が構造化した取り組みで、人々にワクチンを配布するものです。これらのプログラムは、疾病予防の重要性に対する世界の意識の高まりや、政府、国際保健機関、資金提供機関からの強力な支援により、勢いを増しています。予防接種プログラムは、LAPVの広範な配布、安全な投与、高い接種率を確保することでLAPVを支援しており、これらすべてが集団免疫の構築、ウイルス感染の防止、世界のポリオ撲滅という目標の達成に役立っています。例えば、2023年10月、米国疾病予防管理センター（CDC）は、ジフテリア・破傷風・百日咳（DTP）ワクチンの初回接種率が、2021年から2022年にかけて世界全体で86%から89%に上昇したと報告しました。その結果、予防接種プログラムの拡大が弱毒生ポリオワクチンの市場成長を促進すると予想されます。

弱毒生ポリオワクチン市場の主要企業は、自社のワクチンが世界の保健当局によって設定された必要な安全性と有効性の基準を満たしていることを保証するため、規制当局の承認取得に注力しています。規制当局の承認とは、特定の地域や国において、ワクチンなどの製品のマーケティング、販売、使用を許可する、政府の保健機関や規制当局による正式な認可のことです。例えば、2024年7月、インドを拠点とする製薬会社Biological E社は、世界保健機関（WHO）から新規経口ポリオワクチン2型（nOPV2）の承認を取得しました。この次世代型弱毒化生経口ワクチンは、従来の経口ポリオワクチンが抱える課題、特に循環ワクチン由来ポリオウイルス2型（cVDPV2）の集団発生との闘いに、より効果的に対処できるように設計されています。nOPV2は遺伝的安定性を高めるよう設計されており、旧来のワクチンで懸念されていた、ワクチンウイルスが再び強毒型に戻るリスクを低減しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場のマクロ経済シナリオ：金利・インフレ・地政学・貿易戦争・関税・コロナ禍と回復が市場に及ぼす影響を含む

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の弱毒生ポリオワクチン市場：PESTEL分析（政治・社会・技術・環境・法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の弱毒生ポリオワクチン市場：成長率分析
• 世界の弱毒生ポリオワクチンの市場規模・成長率：実績値、2019～2024年
• 世界の弱毒生ポリオワクチンの市場規模・成長率：予測値、2024～2029年、2034年
• 世界の弱毒生ポリオワクチン市場：総有効市場（TAM）

第6章 市場セグメンテーション

• 世界の弱毒生ポリオワクチン市場：ワクチンの種類別、実績値・予測値、2019～2024年、2024～2029年、2034年
• 一価
• 二価
• 三価
• 世界の弱毒生ポリオワクチン市場：投与経路別、実績値・予測値、2019～2024年、2024～2029年、2034年
• 経口投与
• 筋肉内注射
• 皮下注射
• 世界の弱毒生ポリオワクチン市場：年齢層別、実績値・予測値、2019～2024年、2024～2029年、2034年
• 乳児（0～1歳）
• 児童（1～5歳）
• 成人（5歳以上）
• 世界の弱毒生ポリオワクチン市場：エンドユーザー別、実績値・予測値、2019～2024年、2024～2029年、2034年
• 病院
• クリニック
• 公衆衛生機関
• その他のエンドユーザー
• 世界の弱毒生ポリオワクチン市場：一価ワクチンの種類別、実績値・予測値、2019～2024年、2024～2029年、2034年
• mOPV1血清型1の場合
• 世界の弱毒生ポリオワクチン市場：二価ワクチンの種類別、実績値・予測値、2019～2024年、2024～2029年、2034年
• タイプ1
• タイプ3
• 世界の弱毒生ポリオワクチン市場：三価ワクチンの種類別、実績値・予測値、2019～2024年、2024～2029年、2034年
• ポリオウイルス1型
• ポリオウイルス2型
• ポリオウイルス3型

第7章 地域別・国別の分析

• 世界の弱毒生ポリオワクチン市場：地域別、実績値・予測値、2019～2024年、2024～2029年、2034年
• 世界の弱毒生ポリオワクチン市場：国別、実績値・予測値、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 弱毒生ポリオワクチン市場：競合情勢
• 弱毒生ポリオワクチン市場：企業プロファイル
  • Sanofi Pasteur（概要、製品・サービス、戦略、財務分析）
  • GlaxoSmithKline plc（概要、製品・サービス、戦略、財務分析）
  • LG Chem Ltd.（概要、製品・サービス、戦略、財務分析）
  • Serum Institute of India Pvt. Ltd.（概要、製品・サービス、戦略、財務分析）
  • Biological E. Limited（概要、製品・サービス、戦略、財務分析）

第31章 その他の大手企業と革新的企業

• Indian Immunologicals Limited
• Sinovac Biotech Ltd.
• Shenzhen Kangtai Biological Products Co. Ltd.
• Vabiotech
• Emergent BioSolutions Inc.
• Valneva SE
• Bio Farma
• PT Bio Farm
• Bilthoven Bio
• Panacea Biotec
• Haffkine Biopharmaceutical
• Panacea Biotec Ltd.
• Zydus Cadila
• Liaoning Cheng Da Biotechnology Co.Ltd
• Bharat Biotech International Limited

第32章 世界市場：競合ベンチマーキング・ダッシュボード

第33章 主要な企業合併・買収 (M&A)

第34章 最近の市場動向

第35章 市場の潜在力の高い国・部門と戦略

• 弱毒生ポリオワクチン市場：最新機会を提供する国（2029年）
• 弱毒生ポリオワクチン市場：最新機会を提供する部門（2029年）
• 弱毒生ポリオワクチン市場：成長戦略（2029年）
  • 市場動向に基づく戦略
  • 競争戦略

第36章 付録

The live attenuated polio vaccine (LAPV) is an oral polio vaccine (OPV) containing a weakened form of the poliovirus. This form stimulates a robust immune response without causing disease in healthy individuals. It mimics natural infection, providing long-lasting immunity and helping to prevent the transmission of the virus within communities.

The main types of vaccines in live attenuated polio vaccines include monovalent, bivalent, and trivalent. A monovalent oral polio vaccine (mOPV) is specifically designed to protect against a single type of poliovirus, such as type 1, type 2, or type 3. It can be administered orally, via intramuscular injection, or subcutaneously, depending on the age group infants (0-1 years), children (1-5 years), and adults (above 5 years). This vaccine is used by various end-users, including hospitals, clinics, public health agencies, and other healthcare providers.

The live attenuated polio vaccine market research report is one of a series of new reports from The Business Research Company that provides live attenuated polio vaccine market statistics, including live attenuated polio vaccine industry global market size, regional shares, competitors with a live attenuated polio vaccine market share, detailed live attenuated polio vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the live attenuated polio vaccine industry. This live attenuated polio vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The live attenuated polio vaccine market size has grown strongly in recent years. It will grow from $1.85 billion in 2024 to $2.00 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth during the historic period can be attributed to mass immunization campaigns, concerns over vaccine-derived poliovirus, government immunization programs, increased public awareness and education, and greater accessibility and affordability of vaccines.

The live attenuated polio vaccine market size is expected to see strong growth in the next few years. It will grow to $2.71 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth during the forecast period can be attributed to improved vaccine stability and shelf life, a resurgence of polio cases in conflict zones, donor fatigue in eradication efforts, the expansion of routine immunization programs, and increased research and development for safer live attenuated vaccine strains. Key trends expected during this period include the emergence of vaccine-derived poliovirus, the development of new oral polio vaccines, technological advancements in vaccine formulations, the integration of digital technologies, and the strengthening of public-private partnerships.

The expansion of immunization programs is expected to significantly contribute to the growth of the live attenuated polio vaccine (LAPV) market in the coming years. Immunization programs are structured efforts by governments, health organizations, and other institutions to distribute vaccines to populations to prevent the spread of infectious diseases. These programs are gaining momentum due to heightened global awareness about the importance of disease prevention, along with strong support from governments, international health organizations, and funding bodies. Immunization programs support LAPVs by ensuring their widespread distribution, safe administration, and high coverage rates, all of which help build herd immunity, prevent virus transmission, and further the goal of global polio eradication. For example, in October 2023, the Centers for Disease Control and Prevention (CDC) reported that global coverage for the first dose of the diphtheria-tetanus-pertussis (DTP) vaccine increased from 86% to 89% between 2021 and 2022. As a result, the expansion of immunization programs is anticipated to drive market growth for live attenuated polio vaccines.

Leading companies in the live attenuated polio vaccine market are focusing on obtaining regulatory approvals to ensure their vaccines meet the necessary safety and efficacy standards set by global health authorities. Regulatory approvals refer to the formal authorization granted by government health agencies or regulatory bodies that permit the marketing, sale, and use of a product, such as a vaccine, within specific regions or countries. For instance, in July 2024, Biological E, an India-based pharmaceutical company, received approval from the World Health Organization (WHO) for its novel oral polio vaccine type 2 (nOPV2). This next-generation, live attenuated oral vaccine is designed to better address the challenges posed by traditional oral polio vaccines, especially in combating circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreaks. The nOPV2 is engineered for enhanced genetic stability, reducing the risk of the vaccine virus reverting to a virulent form an issue that has been a concern with older vaccines.

In June 2024, SK bioscience, a South Korea-based vaccine and biotechnology company, acquired IDT Biologika for approximately $244 million. This acquisition strengthens SK bioscience's leadership in vaccine development and manufacturing, expanding its capabilities and service offerings to improve global health outcomes. The acquisition also aligns with SK bioscience's long-term goals of operational growth and innovation. IDT Biologika, based in Germany, is a contract development and manufacturing organization specializing in viral vaccines, including live attenuated virus vaccines.

Major players in the live attenuated polio vaccine market are Sanofi Pasteur, GlaxoSmithKline plc, LG Chem Ltd., Serum Institute of India Pvt. Ltd., Biological E. Limited, Indian Immunologicals Limited, Sinovac Biotech Ltd., Shenzhen Kangtai Biological Products Co. Ltd., Vabiotech, Emergent BioSolutions Inc., Valneva SE, Bio Farma, PT Bio Farm, Bilthoven Bio, Panacea Biotec, Haffkine Biopharmaceutical, Panacea Biotec Ltd., Zydus Cadila, Liaoning Cheng Da Biotechnology Co.Ltd, Bharat Biotech International Limited.

North America was the largest region in the live attenuated polio vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in live attenuated polio vaccine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the live attenuated polio vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The live attenuated polio vaccine market consists of sales of monovalent oral polio vaccine (mOPV), bivalent oral polio vaccine (bOPV), novel oral polio vaccine, and trivalent oral polio vaccine (tOPV). Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Live Attenuated Polio Vaccine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on live attenuated polio vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for live attenuated polio vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The live attenuated polio vaccine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Vaccine Type: Monovalent; Bivalent; Trivalent
• 2) By Administration Route: Oral Administration; Intramuscular Injection; Subcutaneous Injection
• 3) By Age Group: Infants (0-1 years); Children (1-5 years); Adults (Above 5 years)
• 4) By End-User: Hospitals; Clinics; Public Health Agencies; Other End-Users
• Subsegments:
• 1) Monovalent: mOPV1 For Serotype 1
• 2) Bivalent: Type 1; Type 3
• 3) Trivalent: Poliovirus Type 1; Poliovirus Type 2; Poliovirus Type 3
• Companies Mentioned: Sanofi Pasteur; GlaxoSmithKline plc; LG Chem Ltd.; Serum Institute of India Pvt. Ltd.; Biological E. Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Live Attenuated Polio Vaccine Market Characteristics

3. Live Attenuated Polio Vaccine Market Trends And Strategies

4. Live Attenuated Polio Vaccine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Live Attenuated Polio Vaccine Growth Analysis And Strategic Analysis Framework

• 5.1. Global Live Attenuated Polio Vaccine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Live Attenuated Polio Vaccine Market Growth Rate Analysis
• 5.4. Global Live Attenuated Polio Vaccine Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Live Attenuated Polio Vaccine Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Live Attenuated Polio Vaccine Total Addressable Market (TAM)

6. Live Attenuated Polio Vaccine Market Segmentation

• 6.1. Global Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monovalent
• Bivalent
• Trivalent
• 6.2. Global Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Administration
• Intramuscular Injection
• Subcutaneous Injection
• 6.3. Global Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Infants (0-1 years)
• Children (1-5 years)
• Adults (Above 5 years)
• 6.4. Global Live Attenuated Polio Vaccine Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Public Health Agencies
• Other End-Users
• 6.5. Global Live Attenuated Polio Vaccine Market, Sub-Segmentation Of Monovalent, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• mOPV1 For Serotype 1
• 6.6. Global Live Attenuated Polio Vaccine Market, Sub-Segmentation Of Bivalent, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type 1
• Type 3
• 6.7. Global Live Attenuated Polio Vaccine Market, Sub-Segmentation Of Trivalent, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Poliovirus Type 1
• Poliovirus Type 2
• Poliovirus Type 3

7. Live Attenuated Polio Vaccine Market Regional And Country Analysis

• 7.1. Global Live Attenuated Polio Vaccine Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Live Attenuated Polio Vaccine Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Live Attenuated Polio Vaccine Market

• 8.1. Asia-Pacific Live Attenuated Polio Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Live Attenuated Polio Vaccine Market

• 9.1. China Live Attenuated Polio Vaccine Market Overview
• 9.2. China Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Live Attenuated Polio Vaccine Market

• 10.1. India Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Live Attenuated Polio Vaccine Market

• 11.1. Japan Live Attenuated Polio Vaccine Market Overview
• 11.2. Japan Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Live Attenuated Polio Vaccine Market

• 12.1. Australia Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Live Attenuated Polio Vaccine Market

• 13.1. Indonesia Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Live Attenuated Polio Vaccine Market

• 14.1. South Korea Live Attenuated Polio Vaccine Market Overview
• 14.2. South Korea Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Live Attenuated Polio Vaccine Market

• 15.1. Western Europe Live Attenuated Polio Vaccine Market Overview
• 15.2. Western Europe Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Live Attenuated Polio Vaccine Market

• 16.1. UK Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Live Attenuated Polio Vaccine Market

• 17.1. Germany Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Live Attenuated Polio Vaccine Market

• 18.1. France Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Live Attenuated Polio Vaccine Market

• 19.1. Italy Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Live Attenuated Polio Vaccine Market

• 20.1. Spain Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Live Attenuated Polio Vaccine Market

• 21.1. Eastern Europe Live Attenuated Polio Vaccine Market Overview
• 21.2. Eastern Europe Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Live Attenuated Polio Vaccine Market

• 22.1. Russia Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Live Attenuated Polio Vaccine Market

• 23.1. North America Live Attenuated Polio Vaccine Market Overview
• 23.2. North America Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Live Attenuated Polio Vaccine Market

• 24.1. USA Live Attenuated Polio Vaccine Market Overview
• 24.2. USA Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Live Attenuated Polio Vaccine Market

• 25.1. Canada Live Attenuated Polio Vaccine Market Overview
• 25.2. Canada Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Live Attenuated Polio Vaccine Market

• 26.1. South America Live Attenuated Polio Vaccine Market Overview
• 26.2. South America Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Live Attenuated Polio Vaccine Market

• 27.1. Brazil Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Live Attenuated Polio Vaccine Market

• 28.1. Middle East Live Attenuated Polio Vaccine Market Overview
• 28.2. Middle East Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Live Attenuated Polio Vaccine Market

• 29.1. Africa Live Attenuated Polio Vaccine Market Overview
• 29.2. Africa Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Live Attenuated Polio Vaccine Market Competitive Landscape And Company Profiles

• 30.1. Live Attenuated Polio Vaccine Market Competitive Landscape
• 30.2. Live Attenuated Polio Vaccine Market Company Profiles
  • 30.2.1. Sanofi Pasteur Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. LG Chem Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Serum Institute of India Pvt. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Biological E. Limited Overview, Products and Services, Strategy and Financial Analysis

31. Live Attenuated Polio Vaccine Market Other Major And Innovative Companies

• 31.1. Indian Immunologicals Limited
• 31.2. Sinovac Biotech Ltd.
• 31.3. Shenzhen Kangtai Biological Products Co. Ltd.
• 31.4. Vabiotech
• 31.5. Emergent BioSolutions Inc.
• 31.6. Valneva SE
• 31.7. Bio Farma
• 31.8. PT Bio Farm
• 31.9. Bilthoven Bio
• 31.10. Panacea Biotec
• 31.11. Haffkine Biopharmaceutical
• 31.12. Panacea Biotec Ltd.
• 31.13. Zydus Cadila
• 31.14. Liaoning Cheng Da Biotechnology Co.Ltd
• 31.15. Bharat Biotech International Limited

32. Global Live Attenuated Polio Vaccine Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Live Attenuated Polio Vaccine Market

34. Recent Developments In The Live Attenuated Polio Vaccine Market

35. Live Attenuated Polio Vaccine Market High Potential Countries, Segments and Strategies

• 35.1 Live Attenuated Polio Vaccine Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Live Attenuated Polio Vaccine Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Live Attenuated Polio Vaccine Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer